Profile image
Senior Research Officer

Dr David van Bockel

Immunovirology and Pathogenesis Program
Phone
+61 2 9385 0471
E-mail
dvanbockel@kirby.unsw.edu.au
Cook L; Zaunders J; Seddiki N; van Bockel D; Kelleher AD; Munier CML, 2023, 'Parallel analysis of multiple human memory CD4+ T-cell subsets within antigen-specific responses using cell proliferation dyes', Immunology and Cell Biology, 101, pp. 171 - 178, http://dx.doi.org/10.1111/imcb.12606
2023
Boyd MA; van Bockel D; Munier CML; Kelleher AD, 2022, 'Navigating the complexity of chronic HIV-1 associated immune dysregulation', Current Opinion in Immunology, 76, http://dx.doi.org/10.1016/j.coi.2022.102186
2022
Cook L; Munier CML; Seddiki N; Hardy MY; Anderson RP; Zaunders J; Tye-Din JA; Kelleher AD; van Bockel D, 2020, 'Circulating gluten-specific, but not CMV-specific, CD39+ regulatory T cells have an oligoclonal TCR repertoire', Clinical and Translational Immunology, 9, pp. e1096, http://dx.doi.org/10.1002/cti2.1096
2020
Nikolayevskyy V; Balabanova Y; Kontsevaya I; Ignatyeva O; Skenders G; Vasiliauskiene E; Bockel DV; Drobniewski F, 2020, 'Biomarkers of treatment success in fully sensitive pulmonary tuberculosis patients: A multicenter longitudinal study', Biomarkers in Medicine, 14, pp. 1439 - 1452, http://dx.doi.org/10.2217/bmm-2020-0246
2020
Van Bockel D; Munier CML; Turville S; Badman SG; Walker G; Stella AO; Aggarwal A; Yeang M; Condylios A; Kelleher AD; Applegate TL; Vallely A; Whiley D; Rawlinson W; Cunningham P; Kaldor J; Guy R, 2020, 'Evaluation of commercially available viral transport medium (VTM) for SARS-CoV-2 inactivation and use in point-of-care (POC) testing', Viruses, 12, pp. 1208, http://dx.doi.org/10.3390/v12111208
2020
Polizzotto M; Van Bockel D; Law C; Roberts J; Buckland G; Just S; Comben S; Hillman R; Gilson R; Pett S; Poynten M; Law M; Kelleher A; Emery S, 2019, 'Clearance of HPV Anal Premalignant Lesions and Modulation of Systemic Immune Responses to HPV Oncogenes with Low Dose Pomalidomide', Annals of Oncology, 30, pp. xi35 - xi35, http://dx.doi.org/10.1093/annonc/mdz451.005
2019
Hey-Nguyen WJ; Bailey M; Xu Y; Suzuki K; Van Bockel D; Finlayson R; Leigh Brown A; Carr A; Cooper DA; Kelleher AD; Koelsch KK; Zaunders JJ, 2019, 'HIV-1 DNA Is Maintained in Antigen-Specific CD4+ T Cell Subsets in Patients on Long-Term Antiretroviral Therapy Regardless of Recurrent Antigen Exposure', AIDS Research and Human Retroviruses, 35, pp. 112 - 120, http://dx.doi.org/10.1089/aid.2018.0235
2019
Kent SJ; Hough S; Kelleher AD; Law MG; Hutchinson J; Catalfarmo M; van Bockel D; Lane C; Baker JV; Emery S; Han A, 2018, 'Vorapaxar for HIV-associated inflammation and coagulopathy (ADVICE): a randomised, double-blind, placebo-controlled trial', The Lancet HIV, 5, pp. e553 - e559, http://dx.doi.org/10.1016/S2352-3018(18)30214-5
2018
Cook L; Munier CML; Seddiki N; van Bockel D; Ontiveros N; Hardy MY; Gillies JK; Levings MK; Reid HH; Petersen J; Rossjohn J; Anderson RP; Zaunders JJ; Tye-Din JA; Kelleher AD, 2017, 'Circulating gluten-specific FOXP3+CD39+ regulatory T cells have impaired suppressive function in patients with celiac disease', Journal of Allergy and Clinical Immunology, 140, pp. 1592 - 1603.e8, http://dx.doi.org/10.1016/j.jaci.2017.02.015
2017
Juno JA; Bockel DV; Kent SJ; Kelleher AD; Zaunders JJ; Munier CML, 2017, 'Cytotoxic CD4 T cells-friend or foe during viral infection?', Frontiers in Immunology, 8, http://dx.doi.org/10.3389/fimmu.2017.00019
2017
Munier CML; van Bockel D; Bailey M; Ip S; Xu Y; Alcantara S; Liu SM; Denyer G; Kaplan W; Suzuki K; Croft N; Purcell A; Tscharke D; Cooper DA; Kent SJ; Zaunders JJ; Kelleher AD, 2016, 'The primary immune response to Vaccinia virus vaccination includes cells with a distinct cytotoxic effector CD4 T-cell phenotype', Vaccine, 34, pp. 5251 - 5261, http://dx.doi.org/10.1016/j.vaccine.2016.09.009
2016
Ladell K; Hashimoto M; Iglesias MC; Wilmann PG; McLaren JE; Gras S; Chikata T; Kuse N; Fastenackels S; Gostick E; Bridgeman JS; Venturi V; Arkoub ZA; Agut H; van Bockel DJ; Almeida JR; Douek DC; Meyer L; Venet A; Takiguchi M; Rossjohn J; Price DA; Appay V, 2013, 'A Molecular Basis for the Control of Preimmune Escape Variants by HIV-Specific CD8+ T Cells', Immunity, 38, pp. 425 - 436, http://dx.doi.org/10.1016/j.immuni.2012.11.021
2013
Zaunders J; van Bockel D, 2013, 'Innate and Adaptive Immunity in Long-Term Non-Progression in HIV Disease', Frontiers in Immunology, 4, http://dx.doi.org/10.3389/fimmu.2013.00095
2013
Seddiki N; Sasson SC; Santner-Nanan B; Munier M; Van Bockel DJ; Ip S; Marriott D; Pett SL; Nanan R; Cooper DA; Zaunders J; Kelleher AD, 2009, 'Proliferation of weakly suppressive regulatory CD4+ T cells is associated with over-active CD4+ T-cell responses in HIV-positive patients with mycobacterial immune restoration disease', European Journal of Immunology, 39, pp. 391 - 403, http://dx.doi.org/10.1002/eji.200838630
2009
Venturi V; Chin HY; Asher TE; Ladell K; Scheinberg P; Bornstein E; Van Bockel D; Kelleher AD; Douek DC; Price DA; Davenport MP, 2009, 'TCR β-chain sharing in human CD8+ T cell responses to cytomegalovirus and EBV', Journal of Immunology, 181, pp. 7853 - 7862, http://dx.doi.org/10.4049/jimmunol.181.11.7853
2009
Streeck H; Van Bockel DJ; Kelleher AD, 2008, 'T-cell responses in primary HIV-1 infection. .', Current opinion in HIV & AIDS, 3, pp. 52 - 59
2008
Venturi V; Chin HY; Asher TE; Ladell K; Scheinberg P; Bornstein E; van Bockel D; Kelleher AD; Douek DC; Price DA; Davenport MP, 2008, 'TCR beta-chain sharing in human CD8+ T cell responses to cytomegalovirus and EBV', Journal of Immunology, 181, pp. 7853 - 7862
2008
Venturi V; Chin H; Asher T; Ladell K; Scheinberg P; Bornstein E; Van Bockel DJ; Kelleher AD; Douek DC; Price DA; Davenport MP, 2007, 'T cell receptor b-chain sharing in human CD8+ T cell responses to cytomegalovirus and Epstein-Barr virus', Journal of Immunology, 181, pp. 7853 - 7862
2007
van Bockel D; Price DA; Asher TE; Venturi V; Suzuki K; Warton K; Davenport MP; Cooper DA; Douek DC; Kelleher AD, 2007, 'Validation of RNA-based molecular clonotype analysis for virus-specific CD8+ T-cells in formaldehyde-fixed specimens isolated from peripheral blood', Journal of Immunological Methods, 326, pp. 127 - 138, http://dx.doi.org/10.1016/j.jim.2007.07.016
2007
Ammaranond P; Zaunders J; Satchell C; Van Bockel DJ; Cooper DA; Kelleher AD, 2005, 'A new variant cytotoxic T lymphocyte escape mutation in HLA-B27-positive individuals infected with HIV type 1', AIDS Research and Human Retroviruses, 21, pp. 395 - 397
2005
Munier CML; Bailey M; Ip S; Xu Y; Alcantara S; Liu SM; van Bockel D; Suzuki K; Cooper DA; Kent SJ; Zaunders JJ; Kelleher AD, 2016, 'The primary immune response to vaccinia virus vaccination includes cells with a distinct cytotoxic effector CD4 T cell phenotype', in EUROPEAN JOURNAL OF IMMUNOLOGY, WILEY-BLACKWELL, AUSTRALIA, Melbourne, Vol. 46, pp. 676 - 677, presented at International Congress of Immunology (ICI), AUSTRALIA, Melbourne, 21 August 2016 - 26 August 2016
2016
Van Bockel DJ; Suzuki K; Warton K; Ammaranond P; Douek D; La Gruta N; Munier M; McGinley C; Nallaiah K; Stanley K; Turner SJ; Zaunders J; Cooper DA; Kelleher AD, 2005, 'TCR clonotypic analysis of CMV antigen-specific CD8+ T-cells from formaldehyde fixed peripheral blood', in Tissue Antigens, Blackwell Munksgaard, pp. 573 - 574
2005

April (2024): The influence of host genetic polymorphisms and phenocopies on the development of human papillomavirus driven anal intraepithelial neoplasia and cancer (Triple-I seed funding) - $75,000

October (2023): Assessment of proviral reservoir characteristics in early HIV infection (St Vincent's Clinic Foundation Research Grant) - $50,000

December (2021): Characterisation and therapeutic harnessing of CD8+ tissue resident memory T (TRM) cell response to high-risk human papillomavirus (HPV)-associated anal squamous intraepithelial lesions (SIL) in the setting of human immunodeficiency virus (HIV) co-infection (National Institutes of Health (NIH), Notification of Special Interest R21 grant) - $450,000AUD

Fundamental basic research and clinical application to address the effect of standard treatment and experimental immunotherapies for infections (and vaccinations) including HPV, HIV and tuberculosis. Extensive experience in the field of immunovirology, lead in the development and completion of multiple national/international clinical trial projects requiring precise laboratory investigations.

Supervision is available for HDR candidates through medical disciplines that include immunology, virology and translational clinical trial research. I have supervised candidates to the completion of PhD and honours programmes, through laboratory based studies and subequent analysis programmes. Areas where I am able to provide supervision to investigate the immunopathogenesis of pathogens include human immunodeficiency virus (HIV-1), human papillomavirus (HPV), tuberculosis and SARS-CoV-2. Specific streams of research within these models include natural history studies, application of immuno- and small-molecule therapies to treat the course of disease as well as treatment options for comorbidities generated as a result of infection.